Tuesday, November 10, 2015

Merck, Eli Lilly targeted in federal drug pricing probe

CNNMoney, in an 11.06.15 post, reports:

Lilly (LLY), based in Indianapolis, said it is being asked about "our treatment of certain distribution service agreements with wholesalers," and how that affects the price it is allowed to charge Medicaid.

New Jersey-based Merck (MRK) said it has been asked for documents related to its "contracting and pricing of Dulera Inhalation Aerosol with...Medicare Part D [drug] plans."

Read more in the current issue of Week in Review>> http://conta.cc/1klcQHS

No comments:

Post a Comment